Find Clinical Trials

Inclusion Criteria: 1. Subjects from 45 to 75 years of age 2. Clinically diagnosed with mild to moderate hypertension and ON or OFF medication (Office SBP \> 140 mmHg and \< 160 mmHg Or ABPM average SBP \> 130 mmHg and \< 145 mmHg), and 3. No significant ECG change reflecting ischemia (i.e. ST elevation or depression) at rest will be recruited to participate in this study. Exclusion Criteria: 1. Subjects will be excluded if pregnant or nursing. 2. Subjects will be excluded if they have coronary disease (by history or on ECG screening), conduction abnormalities on ECG consistent with left bundle branch block, cardiac arrhythmias associated with low blood pressure (\<90 mmHg), peripheral vascular disease, orthopedic disease, diabetic neuropathy or severe hypertension (BP \>170 mmHg systolic or \>110 mmHg diastolic), or any other physical or psychological illness. 3. Those with known sensitivity to any topical preparations or strong reactions to medical dressings and skin tapes also will be excluded. 4. Inability our or unwillingness of individual to give written informed consent.

Inclusion Criteria: Non-smoking (\>6 months) patients with stable moderate-to-severe COPD (post bronchodilator forced expired volume in 1 sec/forced vital capacity\<0.7 and \<lower limit of normal, 30%\<Forced Expired Volume in 1 sec\<80% predicted and exacerbation free for \>6 weeks) will be recruited for the study. Exclusion Criteria: 1. performing structured exercise training (or pulmonary rehabilitation) 2. have a history of deep vein thrombosis 3. are on anticoagulant medication 4. have advanced cardiac or cerebrovascular disease (i.e. heart failure, previous stroke or myocardial infarction) 5. have diabetes 6. have musculoskeletal contraindications that limit their ability to perform physical activity 7. vascular ultrasound measurements cannot be obtained.

Inclusion Criteria: * (PHQ\>8) if depressed * Subjects of any sex aged between 18-70 * Sufficient ability to speak and understand the german language * Ability to understand and sign the informed consent form Exclusion Criteria: * Cognitive impairment that interferes with reliable completion of questionnaires or answering questions * Presence of manic episode, bipolar disorder, Schizophrenia or schizoaffective disorder (as well as other diseases in the F2 domain in the ICD), active eating disorder, active drug or alcohol dependence syndrome * Presence of uncontrolled systemic disease (e.g. autoimmune disease), uncontrolles somatic (other than metabolic or cardiovascular)/ neurologic diseases, current or recent (last month) physical trauma * Patient with acute suicidal ideation * known deficiency of alpha-1-antitrypsin * pregnant or lactating women

Inclusion Criteria: * Participants should have undergone breast conservation therapy with a lumpectomy and axillary evaluation to consist of a sentinel node biopsy or axillary dissection * Confirmation of Triple Negative (TN) breast cancer by tissue biopsy * Adequate tissue to calculate RSI * To fulfill the requirement of HER2- disease, a breast cancer must not demonstrate, at initial diagnosis or upon subsequent biopsy, overexpression of HER2 by either IHC or in-situ hybridization as defined by the ASCO / CAP Guidelines * To fulfill the requirement of hormone receptor (HR)- disease, a breast cancer must express (\<10%), by immunohistochemistry (IHC), the hormone receptors (estrogen receptor \[ER\] and progesterone receptor \[PR\]) as defined in the American Society of Clinical Oncology (ASCO) / College of American Pathologists (CAP) Guidelines * Life expectancy \>16 weeks * KPS ≥ 70 * Age ≥ 18 years * Participants with surgery within 14 days should have recovered from all effects of the surgery and be cleared by their surgeon * There is no limit on prior systemic therapies * Women of childbearing potential and sexually active males must commit to the use of effective contraception while on study * Ability to sign an informed consent form, which can be signed by a family member or health care proxy. Informed consent must be given before study enrollment Exclusion Criteria: * Major surgery or significant traumatic injury that has not been recovered from 14 days before study initiation * Women who are pregnant or breastfeeding * Positive surgical margins * History of allergy or hypersensitivity to any of the study drugs or study drug components * Metastatic breast cancer

Inclusion Criteria: * Provision of signed and dated Informed Consent Form * Stated willingness to comply with all study procedures * Males and Females; Age \>= 18 years * \* Diagnosis of epilepsy: Epilepsy diagnosis based on neurology clinician impression or EEG findings * Anxiety or Depression symptoms * Receiving clinical neurological care at Atrium Health Exclusion Criteria: * Current participation in another treatment of intervention study * Cognitive limitations precluding completion of Anxiety and Depression self-report instruments on paper, electronically, or by interview * Comorbid medical condition with life expectancy less than 6 months * Not a good candidate for collaborative care due to: * Active ongoing treatment by a psychiatrist * Active suicidal ideation * History of past suicide attempt and: * receiving ongoing psychotherapy OR * has seen a psychiatrist in the past year * History of suicide attempt in the past year and: * currently prescribed 2 or more psychotropic medications for psychiatric indication (not merely as a hypnotic) AND not felt to be a good candidate for collaborative care based on the judgement of the investigators * Unstable drug or alcohol abuse For the third Aim (sustainability supplement: intervention only care delivery exploratory study supplement) - the Participants meeting the following criteria may participate * individuals who meet the above INC-EXC criteria and have completed the Control Arm of a collaborative care research study - NCT05559749 - NCT05353452 or * individuals who meet the above INC-EXC criteria except rather than having a diagnosis of Epilepsy; they have a diagnosis of functional neurological disorder with seizures

Inclusion Criteria: * Non-small cell lung cancer with historic PD-L1 ≥ 1%, as determined locally using a clinically accepted assay. Patients must have experienced benefit from previous anti-PD(L)1-containing therapy for at least 4 months based on investigator-assessed disease stability or response prior to developing documented disease progression. Patients must have also received prior platinum-based chemotherapy, either in combination or in sequence with anti-PD-(L)1, unless patient was ineligible to receive such treatment. * Renal cell carcinoma, clear cell histology, previously treated with anti-PD(L)1-containing therapy and a VEGF targeted therapy as monotherapy or in combination. Patients should have documented disease progression following anti-PD(L)1-containing therapy. * Cutaneous melanoma, previously treated with anti-PD(L)1-containing therapy. Patients should have documented disease progression following anti-PD(L)1-containing therapy. Patients with BRAF V600-mutant melanoma must have also received prior therapy with a BRAF V600 inhibitor, with or without a MEK inhibitor. * Ovarian cancer, high-grade serous histology, naïve to anti-PD(L)1 therapy, must have received one prior systemic therapy in platinum-resistant setting. * Nasopharyngeal carcinoma, non-keratinizing locally advanced recurrent or metastatic. Depending on the study arm, patients may be naïve to anti-PD(L)1 therapy, or previously treated with platinum-based chemotherapy with or without anti-PD-(L)1. * Locally advanced unresectable or metastatic triple negative breast cancer, ovarian cancer (high-grade serous histology), anal cancer (squamous), MSI-H CRC, esophagogastric cancer, mesothelioma, and HNSCC. * Locally advanced unresectable or metastatic anal cancer (squamous), thymic carcinoma, MSI-H CRC, esophagogastric cancer, mesothelioma, and HNSCC, all naïve to anti-PD(L)1 therapy and for whom anti PD(L)1 therapy is not available. * Triple negative breast cancer with historic PD-L1 CPS ≥ 1%, must have received at least one line of chemotherapy. In addition, these patients must have previously received sacituzumab govitecan, and in the case of a BRCA mutation a PARP inhibitor, if these treatments are locally approved and accessible to the patient. Exclusion Criteria: * Impaired cardiac function or clinically significant cardiac disease. * Use of agents known to prolong the QT interval unless they can be permanently discontinued for the duration of study. * History of severe hypersensitivity reactions to any ingredient of study drug(s) and other mAbs and/or their excipients. * Active, known or suspected autoimmune disease. Patients with vitiligo, type I diabetes, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur may be considered. Patients previously exposed to anti-PD-1/PD-L1 treatment who are adequately treated for skin rash or with replacement therapy for endocrinopathies should not be excluded. * Any evidence of interstitial lung disease (ILD) or pneumonitis, or a prior history of ILD or non-infectious pneumonitis requiring high-dose glucocorticoids. * Patients who discontinued prior anti-PD-(L)1 therapy due to an anti-PD-(L)1-related toxicity (applicable to the KFA115 in combination with pembrolizumab treatment arms). * Patients with symptomatic peripheral neuropathy limiting instrumental activities of daily living. Other protocol-defined inclusion/exclusion criteria may apply

Inclusion Criteria: * histological or cytological diagnosis of ER+ and HER2- advanced/metastatic breast cancer that is not amendable to surgical resection with curative intent (≥1% ER+ stained cells on the most recent tumor biopsy). * prior anticancer therapies: at least 1 and no more than 2 lines of prior therapies for advanced/metastatic disease; 1 line of any CDK4/6 inhibitor-based regimen is required (independent of the setting eg, adjuvant or advanced/metastatic) * at least 1 measurable lesion as defined by RECIST v1.1. * ECOG PS ≤1. Exclusion Criteria: * visceral crisis at risk of life-threatening complications in the short term * known history of drug-induced pneumonitis or other significant symptomatic deterioration of lung functions. * newly diagnosed brain metastases, or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease. Participants with a history of CNS metastases or cord compression are eligible if they have been definitively treated, clinically stable and discontinued anti-seizure medications and corticosteroids for at least 14 days prior to enrollment in the study. * history of any other tumor malignancies within the past 3 years, except for the following: (1) adequately treated basal or squamous cell carcinoma of the skin; (2) curatively treated in situ carcinoma of the cervix. * inflammatory breast cancer * impaired cardiovascular function or clinically significant cardiovascular diseases * concurrent administration of medications, food, or herb supplements that are strong inhibitors and strong/moderate inducers of CYP3A and drugs known to predispose to Torsade de Pointes or QT interval prolongation. * renal impairment, not adequate liver function and/or bone marrow function * known active infection

Inclusion Criteria: 1. Patient must have signed a written informed consent prior to any trial specific procedures; Note: When the patient is unable to write to give his written consent, a trusted person of their choice, independent from the investigator or the sponsor, can confirm in writing the patient's consent 2. Male or female ≥ 18 years of age; 3. Patients with pathologically documented locally advanced inoperable or metastatic triple negative breast cancer (mTNBC) whose disease has progressed on (neo)adjuvant chemotherapy+/-immunotherapy for early TNBC or within 6 months after the end of any systemic therapy, surgery or radiotherapy with curative intent, whatever comes last. Note: TNBC is defined as the absence of HER2 overexpression by immunohistochemistry (IHC) defined as IHC 0, 1+, or 2+ and fluorescence in situ hybridization \[FISH\] non-amplified and estrogen receptor (ER) expression \<10% and progesterone receptor (PR) expression \<10% by local pathological assessment on the most recent tissue sample collected 4. Prior exposure to a taxane Note: If indicated, prior therapy with ICI for patients with PD1 positive tumor and prior treatment with PARP inhibitor for patients with gBRCAm is required 5. Measurable disease, as defined by RECIST v1.1 6. Patient must have accepted to perform on-treatment biopsies. If the physician considers doing the biopsy on the primary tumor site because accessibility, it can be performed only if the primary tumor site has not been previously irradiated; 7. Have metastatic site easily accessible to biopsy (with exception of bone metastasis) Note 1: Patients with only bone metastasis will be eligible if the primary tumor is accessible for biopsy at inclusion Note 2: If the patient has a single measurable lesion and it is the only one that can be biopsied, the patient cannot be included because the disease is no longer measurable according to RECIST v1.1 8. Eastern Cooperative Oncology Group (ECOG) performance status ≤2; 9. Life expectancy ≥12 weeks; 10. Adequate haematologic and organ function 11. Negative hepatitis B surface antigen (HBsAg) test at screening (patients with a negative HBsAg test and a positive total hepatitis B core antibody (HBcAb) test at screening are eligible), negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening; 12. Evidence of post-menopausal status or negative pregnancy urinary test within 72 hours or serum pregnancy test within 14 days before study treatment and confirmed prior to treatment on Cycle 1 Day 1 for female pre-menopausal patients; 13. Woman of childbearing potential and male patient must agree to use adequate contraception for the duration of trial participation and up to 6 months after completing treatment for women and up to 3 months for men; 14. Patient affiliated to a social security system (or equivalent); 15. Patient is willing and able to comply with the protocol for the duration of the trial including undergoing treatment and scheduled visits, and examinations including follow-up; Exclusion Criteria: 1. Participation in another therapeutic trial within the 30 days prior to C1D1; 2. Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases or evidence of leptomeningeal disease or clinically active spinal cord compression. Patients with stable and asymptomatic brain metastases will be eligible, yet the number will be capped to 15% of the overall population; 3. Previous history of cancer other than mTNBC within 5 years prior to C1D1, except of those with a negligible risk of metastasis or death (e.g., 5-year OS rate \>90%) and treated with curative intent (e.g. carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or stage I uterine cancer); 4. Prior treatment with topoisomerase-1 inhibitor or with ADC containing topoisomerase-1 inhibitor 5. Met any of the following criteria for cardiac disease: 1. Myocardial infarction or unstable angina pectoris within 6 months of enrolment. 2. History of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication); history of QT interval prolongation. 3. New York Heart Association (NYHA) Class III or greater congestive heart failure or left ventricular ejection fraction of \<40%. 6. Severe uncontrolled infection requiring oral or IV antibiotics within 4 weeks prior to C1D1; 7. Major surgical procedure within 4 weeks prior to C1D1; 8. History of severe allergic, anaphylactic, or other hypersensitivity reactions to humanized antibodies; 9. Known hypersensitivity to the study drug, its metabolites, or formulation excipient. 10. Patients receiving concomitant anti-cancer treatments such as chemotherapy, immunotherapy, endocrine therapy and radiotherapy; 11. Patients with unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved according to the common terminology criteria for adverse events of the National Cancer Institute (NCI-CTCAE) v5.0 grade \>2 12. Treatment with systemic corticosteroids dosed at \>20 mg prednisone or equivalent or other systemic immunosuppressive medications within 2 weeks prior to C1D1; 13. Known history of testing positive for HIV or known acquired immunodeficiency syndrome if not controlled; 14. Evidence of significant uncontrolled concomitant disease; 15. Requirement for ongoing therapy with medications that are prohibited or to be used with caution 16. Individuals with physical or psychological conditions considered not to be compatible with the trial; 17. Persons deprived of their liberty or under protective custody or guardianship; 18. Pregnant or breastfeeding women; 19. Patients unwilling or unable to comply with the medical follow-up required by the trial because of geographic, familial, social, or psychological reasons.

Inclusion Criteria: * Patient of one of four medically qualified health care centers and/or OSF HealthCare as defined by insurance type * Insured by Medicaid or dually eligible for Medicare or Medicaid * Has one or more of the three following conditions: Hypertension, Diabetes Mellitus, or Pregnancy * Able to read and understand English or read translated materials in language provided (e.g. Spanish) * Minors who are pregnant and less 18 years of age who are enrolled in the MIC Program Exclusion Criteria: * Not enrolled in the MIC Program * No one will be excluded on basis of sex or race

Inclusion Criteria: * Male and female adolescents ages 15-17; * current MDD diagnosis as determined by K-SADS-PL, * CDRS-R raw score \> 45 (T-score \> 65) at baseline; * estimated full scale IQ \> 80 as determined by the WASI-II; * able to receive outpatient care; * willing to not partake in other psychosocial treatments; * not taking psychotropic medications in the two weeks (four weeks for fluoxetine) prior to consent, with the exception of psychostimulant medication prescribed for the treatment of ADHD. * Additionally, depressed patients must have access to required technology (e.g. smart phone, tablet, or desktop computer) to complete the EMA portion of the study. * Healthy controls cannot not meet criteria for MDD and their CDRS-R raw score must be below 28; T-score \< 52). Exclusion Criteria: * Current or past diagnosis of bipolar, schizophrenia, schizophreniform, schizoaffective disorders, or psychosis NOS; * current diagnosis of developmental disorder, severe conduct disorder, life-threatening anorexia, OCD, or autism-spectrum disorders; * taking psychotropic medications prior to entry; * estimated IQ \< 80; alcohol/drug dependence or abuse within the last 3 months; * potential/confirmed neurological disorder or epilepsy; * claustrophobia; * presence of a medical condition that precludes fMRI; * endorsement of imminent and serious suicidality; * medical conditions that take precedence over the presence of MDD; * pregnancy; * substance use (excluding nicotine) within two weeks of the fMRI scan; * left-handedness; * nicotine use within 3 hours of the fMRI scan; * history of traumatic brain injury or of being unconscious for more than 30 minutes; * a stimulant regime for ADHD which has changed within 30 days of the fMRI scan. * Non-compliance (i.e. \<70% completion) or inability (i.e. lack of smartphone device) to complete the 3 assessment periods of EMA.

Inclusion Criteria: * Self-identify or identified by a parent as African-American or of partly African American ancestry Exclusion Criteria: * Prior hypertension diagnosis * Prescribed BP medication * History of congenital heart disease * History of solid organ transplant * Prescribed and using stimulants and other medications on a regular basis known to raise blood pressure such as testosterone and nicotine replacement

Inclusion Criteria: All participants with or without diabetes: * Have a Body Mass Index (BMI) ≥27 kilogram/square meter (kg/m²) at screening * Diagnosed with chronic kidney disease (CKD) * Has an estimated glomerular filtration rate (eGFR) ≥25 to ≤60 ml/min/1.73 m² or eGFR ≥25 to ≤75 ml/min/1.73 m² if urine albumin-to-creatinine ratio (UACR) \>30 milligram/gram (mg/g) * Have been receiving an angiotensin-converting enzyme (ACE) or angiotensin II receptor blockers (ARB) that is considered the maximal appropriate dose by the investigator for treatment of chronic kidney disease or hypertension (unless the participant has low blood pressure or hypotension) Participants without diabetes: * Have Hemoglobin A1c (HbA1c) \<6.5% at screening Participants with Type 2 diabetes: * Have been diagnosed at least 180 days prior to screening * Have HbA1c ≤9.5% at screening Exclusion Criteria: All participants: * Have a self-reported change in body weight \>5 kilogram (kg) within 90 days prior to screening. * Have a prior or planned surgical treatment for obesity * Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 180 days * Have eGFR \<25 mL/min/1.73m² calculated by using creatinine-based chronic kidney disease epidemiology collaboration (CKD-EPI) equations, as determined by central laboratory at screening. * Have a history of unstable or rapidly progressing renal disease according to investigator judgment * Have a known clinically significant gastric emptying abnormality (for example, severe diabetic gastroparesis or gastric outlet obstruction) or chronically take drugs that directly affect GI motility) * Have had a history of chronic or acute pancreatitis Participants with T2D: * Have history of proliferative diabetic retinopathy or diabetic macular edema or non-proliferative diabetic retinopathy that requires acute treatment. * Have been diagnosed with type 1 diabetes (T1D) or have history of ketoacidosis or hyperosmolar state/coma

Inclusion Criteria: * Mild to moderate major depression * Pregnant at treatment start * Regular contact with maternity mental health clinic * \> 18 years old * Being able to start the treatment earliest in gestational week 8 and latest in gestational week 30 * Stable medication for depression and/or other psychiatric conditions for at least 3 weeks. * Being able to participate in the treatment during the treatment time and having access to and being able to use the internet and mobile phone during the treatment time * Being able to understand the Swedish language orally and in writing Exclusion Criteria: * Montgomery-Åsberg Depression Rating Scale-Self report version (MADRS-S) score below 15 (symptoms of depression to low) or above 35 (severe depression) * High risk of self harm or suicide (based on semi-structured clinical suicide risk assessment) * Psychiatric comorbidity, disability, somatic disorder, or pregnancy complications that prevent treatment participation or that can be negatively affected or compose a risk for the fetus by treatment participation * Ongoing psychological treatment with similar content

1.1 Inclusion criteria Patients are eligible to be included in the study only if all of the following inclusion criteria and none of the exclusion criteria apply: Informed consent 1. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. 2. Provision of signed and dated, written informed consent form prior to any mandatory study specific procedures, sampling, and analyses. Age 3. Subject must be 19 years of age or older at the time of signing the informed consent form. Type of patient and disease characteristics 4. Patients with HR+/HER2- metastatic or inoperable breast cancer 5. Disease progression following treatment with endocrine therapy(ies) and CDK4/6 inhibitor 6. Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below * Hemoglobin ≥ 10.0 g/dL. Red blood cell/plasma transfusion is not permitted within 2 week prior to screening assessment. * Absolute neutrophil count (ANC) ≥ 1.5 x 109/L. Granulocyte colony-stimulating factor administration is not permitted within 1 week prior to screening assessment. * Platelet count ≥ 100 x 109/L. Platelet transfusion is not permitted within 1 week prior to screening assessment. * Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) if no liver metastases; or ≤ 3 × ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastases at baseline. * Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case they must be ≤ 5x ULN * Patients must have creatinine clearance estimated of ≥51 mL/min using the Cockcroft-Gault equation or based on a 24 hour urine test : Estimated creatinine clearance = (140-age \[years\]) x weight (kg) (x F)a serum creatinine (mg/dL) x 72 a where F=0.85 for females and F=1 for males. 7. Eastern Cooperative Oncology Group (ECOG) performance status 0-1. 8. Patients must have a life expectancy ≥ 16 weeks. 9. At least one lesion (measurable and/or non-measurable) that can be accurately assessed at baseline by CT or MRI and is suitable for repeated assessment. Reproduction 10. Postmenopausal or evidence of non-childbearing status for women of childbearing potential. Postmenopausal is defined as: * Amenorrhoeic for 1 year or more following cessation of exogenous hormonal treatments * Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) levels in the postmenopausal range for women under 50 * radiation-induced oophorectomy with last menses \>1 year ago * chemotherapy-induced menopause with \>1 year interval since last menses * surgical sterilisation (bilateral oophorectomy or hysterectomy) OR Pre/peri-menopausal, ie, not meeting the criteria for being post-menopausal. * Pre-/peri-menopausal women can be enrolled if amenable to be treated with monthly LHRH agonists (goserelin or leuprorelin). Participants must have concomitant treatment with LHRH agonists (goserelin or leuprorelin) - which must have been started 3 weeks before Cycle 1 Day 1 - and must be willing to continue on it for the duration of the study. 11. Negative pregnancy test (urine and/or serum) for women of childbearing potential within 28 days of study treatment and confirmed prior to treatment on day 1. 12. Male patients must use a condom during treatment and for 3 months after the last dose of olaparib when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of contraception if they are of childbearing potential Specific criteria for each cohort 13. \<For cohort A\> Patients with known germline or somatic mutations of BRCA1 or BRCA2 14. \<For cohort B\> Patients with known somatic mutations of BRCA1, BRCA2, or other DDR genes (including ATM(ataxia telangiectasia mutated), ATR, BRIP1, PALB2, CHEK1, CHEK2, FANC family, RAD51 family, etc.) Patients with alteration in other DDR genes can be discussed with the principal investigator at the molecular tumour board. 1.2 Exclusion criteria Medical conditions 1. As judged by the investigator, any evidence of condition or illness which in the investigator's opinion makes it undesirable for the patient to participate in the trial. 2. Other malignancy unless curatively treated with no evidence of disease for ≥5 years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS), Stage 1, grade 1 endometrial carcinoma. 3. Resting ECG indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (eg., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, QTcF prolongation \>500 ms, electrolyte disturbances, etc.), or patients with congenital long QT syndrome. 4. Persistent toxicities (\>Common Terminology Criteria for Adverse Event (CTCAE) v5.0 grade 2) caused by previous cancer therapy, excluding alopecia grade 2. 5. Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of MDS(myelodysplastic syndrome)/AML(Acute Myelogenous Leukemia ) 6. Patients with symptomatic uncontrolled brain metastases. A scan to confirm the absence of brain metastases is not required. The patient can receive a stable dose of corticosteroids (up to 10 mg prednisone/day or equivalent) before and during the study as long as these were started at least 4 weeks prior to treatment. Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days. 7. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent. 8. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication. 9. Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV). 10. Patients with known active hepatitis (i.e. Hepatitis B or C). * Active hepatitis B virus (HBV) infection is defined by a positive HBV surface antigen (HBsAg) and positive titer for HBV DNA.result. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody and absence of HBsAg or deoxyribonucleic acid \[DNA\]-negative) are eligible. * Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA. 11. Underweight populations - ≤30kg 12. History of bleeding diathesis (ie, disseminated intravascular coagulation, clotting factor deficiency) or long-term anticoagulant therapy (although patients treated with anti-platelet therapy and low dose warfarin or other anticoagulant agents such as acenocoumarol are eligible providing they have an international normalised ratio \[INR(international normalized ratio)\] of ≤1.6) Prior/concomitant therapy 13. Any previous treatment with fulvestrant, other study drugs (including olaparib or study drugs in each arms), or other investigational agents directly targeting DNA damage response. 14. Patients receiving any s

Inclusion Criteria: * Ability to provide signed and dated informed consent form. Patients willing to comply with all study procedures and be available for the duration of the study. Male or female patients aged 18 to 99 Patients in good general health as evidenced by ability to come to their appointment on day of study. Exclusion Criteria: * Patients age less than 18 years Patients unable or unwilling to provide informed consent to participate in the study Patients for which an accurate tonometry reading cannot be performed. This may include those with blepharospasm (lid squeezers), nystagmus, extensive corneal pathology, or contact lens wearers who cannot remove their contact lens.Patients with significant scleral thinning Patients with a known allergy to proparacaine or fluorescein as these are used to anesthetize and allow measurement respectively of the eye when used with the Goldmann tonometer.

Inclusion Criteria: * Doctor diagnosed asthma; * Incompletely controlled asthma or worse: Asthma Control Questionnaire (ACQ5) score ≥0.8; * Residence (or asthma treatment program) in Region Zealand, Denmark; * Able to read and understand Danish or available assistance to help understand information material, intervention content and respond to questionnaires. Exclusion Criteria: * Unwilling to participate; * Unable to participate in the intervention due to physical or mental condition.

Inclusion Criteria: * breast cancer patient * current endocrine therapy (AI or SERM) * postmenopausal status, defined by: * 12 months amenorrhoea or * 6 months amenorrhoe and FSH level of \>40 mIU/mL or \*\>6 weeks after bilateral oophorectomy or * induced postmenopause (ovarian function suppression using GnRH-analogue) * presence of one or more symptoms of vulvovaginal atrophy (dyspareunia, dryness, irritation) Exclusion Criteria: * a history of vulvar or vaginal surgery (Inclusion is possible after hysterectomy. For these subjects no microbiome sampling will be performed. Microbiome analysis is not performed for these subjects.) * current other vulvar or vaginal disease * recent use of antibiotics/antifungals/corticosteroids (less than 1 month) * current use of vaginal hormonal treatment or vaginal moisturizer: inclusion is possible after a washout period of 4 weeks

Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Pregnant Black individuals, at least 18 years of age 4. English speaking 5. Access to a tablet, smartphone, or computer capable of running the apps Exclusion Criteria: 1. Psychosis 2. Perinatal loss 3. Individuals outside of the US

Inclusion Criteria: 1. 18 years of age or older 2. Discharged from hospital or seen within 48 hours of discharge at Health Sciences North (HSN), William Osler Health Systems (WOHS), Women's College Hospital (WCH), and Markham Stouffville Hospital (MSH). 3. Have at least one complex chronic condition (i.e., heart failure, complex obstructive pulmonary disease (COPD), hypertension, diabetes, and/or depression) that would benefit if monitored through telemonitoring. 4. Able to comply with use of the telemonitoring application and applicable peripheral devices (e.g., able to stand on the weight scale, able to answer symptom questions, etc.) 5. Able to read, write and speak English or have a caregiver who is able to do so on their behalf. 6. Patients must have been discharged from hospital within 2 weeks during their recruitment into the study (or will be recruited prior to their discharge). Exclusion Criteria: 1\. Patients who are discharged from hospital with the intent to be admitted to a long-term care facility will be excluded.

Inclusion Criteria: * Age between 18 and 39 years at the time of signing the informed consent * Patient who speaks and understands French * Signed study informed consent form obtained prior to any study related procedures * At minimum, a moderate (\>3) fatigue level according to the Standard Rating Scale (NRS) 1 month after completion of acute treatment; as measured at the Survivorship of the standard program * Patient with either: curative breast cancer (AJCC stage I-II-III) or a germ cell tumor Exclusion Criteria: * Refusal to participate in the study * Patient having chosen to participate in another psychosocial intervention study for the duration of the study. * Patients with AJCC stage IV breast cancer